Viking Therapeutics, Inc.NASDAQ: VKTX

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

· Issued by Viking Therapeutics, Inc.

On 6ix: 6ix.com/news/viking-therapeutics-announces-positive-52-week-histologic-data-phase-2b-voyage-study

Watch Viking Therapeutics' latest callViking Therapeutics (NASDAQ:VKTX) Q2 2026 Earnings Call · Replay · Jul 29Read the transcript of Viking Therapeutics (NASDAQ:VKTX) Q2 2026 Earnings Call
Viking Therapeutics' next earnings callViking Therapeutics (NASDAQ:VKTX) Q3 2026 Earnings Call · Oct 28, 2026 at 4:30 PM EDTRegister

Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001)

Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p

Viking Therapeutics, Inc. on 6ix

Story so far

Earlier from Viking Therapeutics

Later from Viking Therapeutics

All Viking Therapeutics news releases